-
| Exchange | NASDAQ |
|---|---|
| CurrencyCode | USD |
| ISIN | None |
| Sector | Healthcare |
| Industry | Medical Devices |
| Beta | -0.42 |
|---|---|
| Market Cap | 9M |
| PE Ratio | None |
| Target Price | 5 |
| Dividend Yield | None |
20/20 Biolabs, Inc. develops and commercializes AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. It provides OneTest for Cancer, a multi-cancer early detection, or MCED and OneTest for Longevity, which measures inflammatory biomarkers. It also operates the Clinical Lab Innovation Axcelerator (CLIAx), a CLIA laboratory for overseas diagnostics start-ups. The company was formerly known as 20/20 GeneSystems, Inc. and changed its name to 20/20 Biolabs, Inc. in March 2025. The company was incorporated in 2000 and is based in Gaithersburg, Maryland.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for AIDX using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2026